If there's going to be a big row about executive pay then you'd expect it to happen at GlaxoSmithKline's annual shareholder meeting. The pharmaceutical giant has a track record of annoying investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback